Resurgent global M&A activity, on pace for $4 trillion in deal value in 2026 amid megadeals and AI-driven consolidation, shapes trader sentiment for acquisitions before 2027. Lower interest rates, record equity valuations, and private equity monetization are spurring corporates and sponsors to pursue scale in technology, healthcare, and utilities, with U.S. volumes already nearly double year-ago levels through mid-year. Biotech targets with late-stage data readouts and tech platforms facing valuation resets remain focal points, while regulatory scrutiny on large combinations and carve-out activity introduce uncertainty. Key near-term catalysts include pending approvals for major pending transactions and upcoming earnings that could trigger strategic reviews.